Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioSig Technologies, Inc. - Common Stock (NQ: BSGM )

0.9400 +0.0300 (+3.30%)
Streaming Delayed Price Updated: 3:59 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BioSig Technologies, Inc. - Common Stock

< Previous 1 2 Next >
OTC Markets Group Announces Quarterly Index Performance and Rebalancing
From OTC Markets
Via GlobeNewswire
BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Technologies’ Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
Mr. Amato will also serve on the Company’s Board of Directors 
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Engages Consulting Firm for Business Model Strategies
BAIPC will work to deploy a series of solutions to transform BioSig’s future course 
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Announces Reduction of its Workforce
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases
Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately 66%. 
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024 
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care
PURE EP™ subscriber community now includes two of top three U.S. health systems in cardiology: Mayo Clinic-Phoenix and Cleveland Clinic 
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP
32-year career in medical device and electrophysiology business expansion for industry bellwethers; led multiple company exits including a $1B sale in 2018 Part of leadership team that grew Johnson &... 
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI
IP portfolio includes U.S. and worldwide utility and design patents and pending applications in the U.S., Europe, and Asia-Pacific 
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig AI Sciences Achieves Infrastructure and Technology progress in Development of Generative AI Platform for Hospitals
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations
Cleveland Clinic, the #1 heart center in the Nation, signs on as first subscriber to receive latest software advancements in intracardiac signal visualization 
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig's PURE EP™ Platform Debuts New Automated Features in First Patient Cases
Latest Software Release Supports Electrophysiologists with Visualizing Heart Patterns Difficult to Recognize with the Naked Eye 
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig AI Sciences Receives $2.2 Million in Seed Funding to Advance Development of Artificial Intelligence Applications
Deal to create additional value through subsidiary to advance Artificial Intelligence strategy without dilution to BioSig Technologies Shareholders 
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig AI Sciences Selected for NVIDIA Inception Partnership Program to Support R&D Collaboration on AI Medical Device Platform for Hospitals
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Joins Webull Corporate Connect
Webull’s investor community can now access real-time BioSig investor communications and Q&A 
From BioSig Technologies, Inc.
Via GlobeNewswire
BioSig Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare
From BioSig Technologies, Inc.
Via GlobeNewswire
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Via ACCESSWIRE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.